Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more
Kyongbo Pharmaceutical Co Ltd (214390) - Net Assets
Latest net assets as of September 2025: ₩145.28 Billion KRW
Based on the latest financial reports, Kyongbo Pharmaceutical Co Ltd (214390) has net assets worth ₩145.28 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩316.49 Billion) and total liabilities (₩171.21 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩145.28 Billion |
| % of Total Assets | 45.9% |
| Annual Growth Rate | 7.9% |
| 5-Year Change | -6.35% |
| 10-Year Change | 19.0% |
| Growth Volatility | 23.68 |
Kyongbo Pharmaceutical Co Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Kyongbo Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kyongbo Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual net assets of Kyongbo Pharmaceutical Co Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩146.15 Billion | +1.23% |
| 2023-12-31 | ₩144.38 Billion | +0.47% |
| 2022-12-31 | ₩143.70 Billion | -1.37% |
| 2021-12-31 | ₩145.70 Billion | -6.64% |
| 2020-12-31 | ₩156.06 Billion | +4.62% |
| 2019-12-31 | ₩149.16 Billion | +0.10% |
| 2018-12-31 | ₩149.01 Billion | +5.30% |
| 2017-12-31 | ₩141.51 Billion | +9.36% |
| 2016-12-31 | ₩129.40 Billion | +5.36% |
| 2015-12-31 | ₩122.82 Billion | +79.74% |
| 2014-12-31 | ₩68.33 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kyongbo Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 92.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩98.33 Billion | 67.28% |
| Other Components | ₩47.82 Billion | 32.72% |
| Total Equity | ₩146.15 Billion | 100.00% |
Kyongbo Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Kyongbo Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Top High Image
TWO:3284
|
$34.25 Million |
|
YAS Co., Ltd.
KQ:255440
|
$34.26 Million |
|
Archer Materials Limited
PINK:ARRXF
|
$34.27 Million |
|
Medicalg
WAR:MDG
|
$34.29 Million |
|
DigitalX Limited
OTCQB:DGGXF
|
$34.24 Million |
|
Ribbon Acquisition Corp Unit
NASDAQ:RIBBU
|
$34.23 Million |
|
Jung Shing Wire Co Ltd
TW:1617
|
$34.23 Million |
|
PNB Gilts Limited
NSE:PNBGILTS
|
$34.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kyongbo Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 144,381,421,250 to 146,154,021,770, a change of 1,772,600,520 (1.2%).
- Net income of 4,639,325,800 contributed positively to equity growth.
- Dividend payments of 1,195,343,000 reduced retained earnings.
- Other factors decreased equity by 1,671,382,280.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩4.64 Billion | +3.17% |
| Dividends Paid | ₩1.20 Billion | -0.82% |
| Other Changes | ₩-1.67 Billion | -1.14% |
| Total Change | ₩- | 1.23% |
Book Value vs Market Value Analysis
This analysis compares Kyongbo Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.73x to 0.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | ₩3172.81 | ₩5490.00 | x |
| 2015-12-31 | ₩5395.38 | ₩5490.00 | x |
| 2016-12-31 | ₩5407.92 | ₩5490.00 | x |
| 2017-12-31 | ₩5916.15 | ₩5490.00 | x |
| 2018-12-31 | ₩6237.22 | ₩5490.00 | x |
| 2019-12-31 | ₩6237.21 | ₩5490.00 | x |
| 2020-12-31 | ₩6527.70 | ₩5490.00 | x |
| 2021-12-31 | ₩6103.93 | ₩5490.00 | x |
| 2022-12-31 | ₩6011.00 | ₩5490.00 | x |
| 2023-12-31 | ₩6039.33 | ₩5490.00 | x |
| 2024-12-31 | ₩6113.48 | ₩5490.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kyongbo Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.94%
- • Asset Turnover: 0.84x
- • Equity Multiplier: 1.94x
- Recent ROE (3.17%) is below the historical average (6.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 12.64% | 5.09% | 1.01x | 2.46x | ₩1.80 Billion |
| 2015 | 21.26% | 14.67% | 0.91x | 1.59x | ₩13.83 Billion |
| 2016 | 9.82% | 6.80% | 0.92x | 1.57x | ₩-234.30 Million |
| 2017 | 12.69% | 9.37% | 0.94x | 1.45x | ₩3.81 Billion |
| 2018 | 8.80% | 6.51% | 0.91x | 1.49x | ₩-1.79 Billion |
| 2019 | 3.54% | 2.76% | 0.81x | 1.59x | ₩-9.63 Billion |
| 2020 | 6.03% | 4.37% | 0.85x | 1.62x | ₩-6.20 Billion |
| 2021 | -5.14% | -4.39% | 0.72x | 1.63x | ₩-22.07 Billion |
| 2022 | 0.42% | 0.31% | 0.82x | 1.67x | ₩-13.76 Billion |
| 2023 | 2.06% | 1.37% | 0.81x | 1.84x | ₩-11.46 Billion |
| 2024 | 3.17% | 1.94% | 0.84x | 1.94x | ₩-9.98 Billion |
Industry Comparison
This section compares Kyongbo Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kyongbo Pharmaceutical Co Ltd (214390) | ₩145.28 Billion | 12.64% | 1.18x | $34.24 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |